| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0031-3955(05)70272-8 |
| P698 | PubMed publication ID | 11130997 |
| P2093 | author name string | Straus SE | |
| Fleisher TA | |||
| Bleesing JJ | |||
| P2860 | cites work | Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II | Q22010404 |
| Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease | Q28115268 | ||
| Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand | Q28513283 | ||
| Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis | Q30080034 | ||
| An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome | Q33328425 | ||
| Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia. | Q33330741 | ||
| Chronic pseudomalignant immuneproliferation (Canale-Smith syndrome) (author's transl) | Q33345710 | ||
| Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity | Q33488225 | ||
| Clinical, immunological, and pathological consequences of Fas-deficient conditions | Q33496872 | ||
| Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity | Q33497763 | ||
| Correction of Fas (CD95) deficiency by haploidentical bone marrow transplantation. | Q33500292 | ||
| Faces and phases of human CD8 T-cell development. | Q33594124 | ||
| The role of Fas and related death receptors in autoimmune and other disease states | Q33636111 | ||
| Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment | Q33652471 | ||
| The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations | Q33747849 | ||
| Revision of the diagnosis of T-zone lymphoma in the father of a patient with autoimmune lymphoproliferative syndrome type II. | Q33751250 | ||
| The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations | Q33836041 | ||
| Chronic lymphoproliferative disorders: an integrated point of view for the differential diagnosis | Q33837941 | ||
| Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance | Q34389314 | ||
| Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease | Q34602392 | ||
| Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia. | Q35132088 | ||
| CD5 B cells in autoimmunity | Q35321025 | ||
| A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease | Q35604700 | ||
| Pathological findings in human autoimmune lymphoproliferative syndrome | Q35754536 | ||
| Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma | Q35787084 | ||
| A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice | Q36367334 | ||
| Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions | Q36400965 | ||
| Reversible monoclonal lymphadenopathy in autoimmune lymphoproliferative syndrome with functional FAS (CD95/APO-1) deficiency | Q38467986 | ||
| Fas gene mutation in the progression of adult T cell leukemia | Q40962746 | ||
| Lymphadenopathy in children | Q45113420 | ||
| The use of the anti-malaria drug Fansidar (pyrimethamine and sulphadoxine) in the treatment of a patient with autoimmune lymphoproliferative syndrome and Fas deficiency | Q47720590 | ||
| Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. | Q54089913 | ||
| Interleukin-2 reverses the defect in activation-induced apoptosis in T cells from autoimmune lpr mice. | Q54139209 | ||
| Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome | Q55670225 | ||
| Phenotypical and Functional Characterization of Double-Negative (CD4-CD8-) alphabeta T-Cell Receptor Positive Cells from an Immunodeficient Patient | Q56112112 | ||
| Dyserythropoiesis associated with a Fas-deficient condition in childhood | Q57078479 | ||
| Increased spontaneous in vitro apoptosis in double negative T cells of humans with a fas/apo-1 mutation | Q57956205 | ||
| Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis | Q58435123 | ||
| Chronic lymphadenopathy simulating malignant lymphoma | Q59242110 | ||
| Novel T-lymphocyte population in combined immunodeficiency with features of graft-versus-host disease | Q69741242 | ||
| Chronic lymphoproliferative disorders | Q73196685 | ||
| Somatic mutations of Fas (Apo-1/CD95) gene in cutaneous squamous cell carcinoma arising from a burn scar | Q73322019 | ||
| Novel Fas (CD95/APO-1) mutations in infants with a lymphoproliferative disorder | Q74418696 | ||
| Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation | Q77169432 | ||
| The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis | Q77577103 | ||
| Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease | Q77787538 | ||
| P433 | issue | 6 | |
| P921 | main subject | autoimmune lymphoproliferative syndrome | Q1151300 |
| P304 | page(s) | 1291-1310 | |
| P577 | publication date | 2000-12-01 | |
| P1433 | published in | Pediatric Clinics of North America | Q7159204 |
| P1476 | title | Autoimmune lymphoproliferative syndrome. A human disorder of abnormal lymphocyte survival | |
| P478 | volume | 47 |
| Q34600681 | 'Activation-induced cell death': a special program able to preserve the homeostasis of the skin? |
| Q35008567 | A review on peripheral blood CD4+ T lymphocyte counts in healthy adult Indians |
| Q24623371 | Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS) |
| Q37106302 | Approach to the patient with recurrent infections |
| Q33404099 | Auto-immune lymphoproliferative disorder and other secondary immune thrombocytopenias in childhood |
| Q35074313 | Autoimmune lymphoproliferative syndrome: etiology, diagnosis, and management |
| Q34513178 | Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype |
| Q48248134 | Autoimmune lymphoproliferative syndrome: molecular diagnosis in two families |
| Q47151016 | Autoimmune lymphoproliferative syndrome: more than a FAScinating disease. |
| Q34440616 | Clues to immune tolerance: the monogenic autoimmune syndromes |
| Q34572227 | Cytokines and autoimmunity |
| Q33411497 | Diagnosis and management of autoimmune cytopenias in childhood |
| Q35542370 | Establishment of adult peripheral blood lymphocyte subset reference range for an Asian population by single-platform flow cytometry: influence of age, sex, and race and comparison with other published studies |
| Q78861591 | Fas ligand gene polymorphisms are not associated with Hashimoto's thyroiditis and Graves' disease |
| Q34786280 | Free radical theory of autoimmunity |
| Q35122240 | Genetic and molecular genetic studies in the diagnosis of atypical lymphoid hyperplasias versus lymphoma |
| Q37142878 | Genetic defects of apoptosis and primary immunodeficiency |
| Q34223137 | Immunophenotyping |
| Q37432231 | Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies |
| Q34239719 | New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome |
| Q37248354 | Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease |
| Q33394927 | Pentostatin for treatment of refractory autoimmune lymphoproliferative syndrome |
| Q24685850 | Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS) |
| Q85215780 | Reduction of splenic volume by steroid therapy in cases with autoimmune pancreatitis |
| Q28210645 | Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: preliminary results of a clinical cohort study and molecular observations |
| Q24632569 | Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop |
| Q42953771 | Targeting Notch signaling in autoimmune and lymphoproliferative disease |
| Q26829652 | Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies |
| Q46919587 | The genetics of systemic lupus erythematosus stratified by renal disease: linkage at 10q22.3 (SLEN1), 2q34-35 (SLEN2), and 11p15.6 (SLEN3). |
| Q36942513 | Tolerance and autoimmunity: lessons at the bedside of primary immunodeficiencies |
| Q24650472 | Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome |
| Q33420245 | Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS). |
Search more.